You are here

Closed

Reset

NOTE: The Solicitations and topics listed on this site are copies from the various SBIR agency solicitations and are not necessarily the latest and most up-to-date. For this reason, you should visit the respective agency SBIR sites to read the official version of the solicitations and download the appropriate forms and rules.

Displaying 17901 - 17910 of 18924 results
  1. 24-PH2: Survivability of Hazardous Materials Placards

    Release Date: 02-08-2024Open Date: 02-08-2024Due Date: 03-07-2024Close Date: 03-07-2024

    24-PH2 FY24.1 DOT SBIR Solicitation Department of Transportation ...

    SBIRPhase IDepartment of Transportation
  2. 24-PH3: Non-Destructive Testing of High-Pressure Cylinders

    Release Date: 02-08-2024Open Date: 02-08-2024Due Date: 03-07-2024Close Date: 03-07-2024

    24-PH3 FY24.1 DOT SBIR Solicitation Department of Transportation ...

    SBIRPhase IDepartment of Transportation
  3. 24-PH4: Rail Car Coupling Monitoring

    Release Date: 02-08-2024Open Date: 02-08-2024Due Date: 03-07-2024Close Date: 03-07-2024

    24-PH4 FY24.1 DOT SBIR Solicitation Department of Transportation ...

    SBIRPhase IDepartment of Transportation
  4. 24-PH5: Biodegradable Casting for Fireworks

    Release Date: 02-08-2024Open Date: 02-08-2024Due Date: 03-07-2024Close Date: 03-07-2024

    24-PH5 FY24.1 DOT SBIR Solicitation Department of Transportation ...

    SBIRPhase IDepartment of Transportation
  5. RFA-DA-25-052: Tools for decentralized clinical trials for substance use disorder (R43/R44 Clinical Trials Optional)

    Release Date: 10-25-2023Open Date: 02-14-2024Due Date: 03-14-2024Close Date: 03-15-2024

    Substance use disorder (SUD) clinical trials traditionally perform recruitment, enrollment, interventions, as well as information collection at the clinical trial sites. In-person visits at the sites are used for screening, assignment to interventions, treatment or other intervention, follow up, as well as collection of information from participants and entering it in a database. Some of the in-p ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  6. RFA-DA-25-051: Tools for Decentralized Clinical Trials for Substance Use Disorder (R41/R42 Clinical Trials Optional)

    Release Date: 10-25-2023Open Date: 02-14-2024Due Date: 03-14-2024Close Date: 03-15-2024

    Substance use disorder (SUD) clinical trials traditionally perform recruitment, enrollment, interventions, as well as information collection at the clinical trial sites. In-person visits at the sites are used for screening, assignment to interventions, treatment or other intervention, follow up, as well as collection of information from participants and entering it in a database. Some of the in-p ...

    STTRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  7. RFA-TR-24-001: Basket Clinical Trials of Drugs Targeting Shared Molecular Etiologies in Multiple Rare Diseases (U44 Clinical Trial Required)

    Release Date: 12-01-2023Open Date: 12-04-2023 Due Dates: Multiple Close Date: 03-16-2024

    While there are thousands of rare diseases, the number of underlying etiologies is much smaller. Moreover, many disease etiologies underlie multiple traditional diseases. This is most readily seen for rare monogenic diseases, where the most common etiologies include premature termination codons, protein misfolding, and abnormal RNA splicing. Other examples of rare disease shared molecular etiologi ...

    SBIRPhase IIDepartment of Health and Human ServicesNational Institutes of Health
  8. RFA-AA-24-001: High-Throughput Screening (HTS) Platform for Discovery of Medications to Treat Alcohol Use Disorder (R43/R44 Clinical Trials Not Allowed)

    Release Date: 12-21-2023Open Date: 03-05-2024Due Date: 04-09-2024Close Date: 04-10-2024

    Drug development is challenging, particularly for Central Nervous System (CNS) medications. It takes approximately 18 years to move a potential CNS medication from its initial discovery phase to the marketplace, often costing several billion dollars. The failure rate is high (only 8% of new CNS compounds entering Phase I studies will reach the market) and contributes to the high costs and slow rat ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  9. RFA-AA-24-002: High-Throughput Screening (HTS) Platform for Discovery of Medications to Treat Alcohol Use Disorder (R41/R42 Clinical Trials Not Allowed)

    Release Date: 12-21-2023Open Date: 03-05-2024Due Date: 04-09-2024Close Date: 04-10-2024

    Drug development is challenging, particularly for Central Nervous System (CNS) medications. It takes approximately 18 years to move a potential CNS medication from its initial discovery phase to the marketplace, often costing several billion dollars. The failure rate is high (only 8% of new CNS compounds entering Phase I studies will reach the market) and contributes to the high costs and slow rat ...

    STTRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  10. HHS-2024-ACL-NIDILRR-BISB-0070: Small Business Innovation Research Program (SBIR) Phase II

    Release Date: 01-05-2024Open Date: 01-05-2024Due Date: 03-05-2024Close Date: 03-05-2024

    The purpose of the Federal SBIR program is to stimulate technological innovation in the private sector, strengthen the role of small business in meeting Federal research or research and development (R/R&D) needs, and improve the return on investment from Federally-funded research for economic and social benefits to the nation. The specific purpose of NIDILRR's SBIR program is to improve the lives ...

    SBIRPhase IIDepartment of Health and Human ServicesAdministration for Community Living
US Flag An Official Website of the United States Government